54,4 %The overall observed survival in the study cohort was 54.4% at 3 years.
Kenyaovarian cancerpublié 2024International journal of cancereurope_pmcdocument de 14 observations
Palier Gold : evidences validées mécaniquement, avec leur source primaire.
6 677 evidences · page 42 / 268
54,4 %The overall observed survival in the study cohort was 54.4% at 3 years.
Kenyaovarian cancerpublié 2024International journal of cancereurope_pmcdocument de 14 observations
12,4 %Among 2386 partners of HIV-positive persons who inject drugs in Kenya, 297 (12.4%) tested HCV antibody positive.
Kenyahépatite Cpublié 2022BMC infectious diseasesPubMeddocument de 4 observations
1,51 relative_riskWomen living with HIV with CD4+ T cells of less than 200 cells/μl had a 1.51-fold increased risk of having high-risk HPV.
Kenyahigh-risk HPVpublié 2023AIDS (London, England)PubMeddocument de 9 observations
3,8 RRAbuse was associated with moderate-to-severe depressive symptoms with a relative risk of 3.8.
Kenyadepressive symptomspublié 2022Journal of acquired immune deficiency syndromes (1999)PubMeddocument de 14 observations
23 %Of 2,117 women, 23% reported breast complaints.
Kenyabreast complaintsobservé 2019 and 2020publié 2026JCO global oncologyPubMeddocument de 10 observations
4 foldThere was a four fold higher rate of cerebral malaria among malaria patients at Kilifi compared with Ifakara.
Kenyapaludismepublié 1994Acta tropicaeurope_pmcdocument de 4 observations
515 000 infantsGlobally, approximately 515,000 infants with Sickle Cell Disease (SCD) are born every year.
Kenyadrépanocytosepublié 2026Annals of global healthPubMeddocument de 5 observations
Less than half of the included patients were alive 3 years after a cancer diagnosis for non-Hodgkin lymphoma in sub-Saharan Africa.
Kenyanon-Hodgkin lymphomapublié 2024The Lancet. Global healtheurope_pmcdocument de 12 observations
0,8 aORHaving more viral load results available for analysis was associated with lower odds of sustained viral suppression (adjusted odds ratio 0.80; 95% CI 0.71, 0.90).
KenyaVIH/sidapublié 2026Journal of the Pediatric Infectious Diseases SocietyPubMeddocument de 9 observations
4,73 %Hepatitis B virus (HBV) accounted for 4.73% of discarded blood units due to transfusion transmissible infections at the Kwale Satellite Blood Transfusion Centre in Kenya from 2018 to 2022.
Kenyahépatite Bobservé 2018-2022publié 2024BMC public healthPubMeddocument de 7 observations
18,4 %Out of the 37 (18.4%) who returned for follow up at 2 weeks, none was either sputum smear positive or Gene-Xpert positive.
Kenyatuberculoseobservé February 2013 to February 2014publié 2019African Journal of Health SciencesOpenAlexdocument de 5 observations
0 %The sensitivity of the WHO symptom screen for tuberculosis was 0% among people living with HIV receiving antiretroviral therapy in western Kenya.
Kenyatuberculosepublié 2021BMC infectious diseasesPubMeddocument de 12 observations
79 %1460 (79%) of the 1845 analyzed AHD participants were WHO stage III/IV at enrollment.
KenyaVIH/sidaobservé October 2016 to September 2019publié 2023MedicinePubMeddocument de 14 observations
22,1 %22.1% of participants had both hypertension and diabetes.
Kenyadiabète (non précisé) · hypertension artériellepublié 2023BMJ openPubMeddocument de 6 observations
32 %32% of uncomplicated fevers were managed at home without the use of modern medicines in Kenya between 2001 and 2002.
Kenyafeverobservé 2001 and 2002publié 2006BMC public healtheurope_pmcdocument de 10 observations
5,5 %Among 1276 pregnant Kenyan women, 70 (5.5%) tested positive for Chlamydia trachomatis.
KenyaChlamydia trachomatispublié 2024Sexually transmitted diseasesPubMeddocument de 7 observations
68,8 %The prevalence of persistent respiratory symptoms was 68.8% in rural settings among individuals in low- and middle-income countries.
Kenyapersistent respiratory symptomspublié 2022PLOS global public healtheurope_pmcdocument de 11 observationsDOI 10.1371/journal.pgph.0000805
0,2 odds_ratioGrip strength was associated with a lower risk of type 2 diabetes (adjusted odds ratio = 0.20, 95% confidence interval 0.08–0.45, P < 0.001, per standard deviation increase).
Kenyadiabète de type 2publié 2021Tropical medicine & international health : TM & IHPubMeddocument de 4 observations
27,2 %The use of three or more doses of IPTpSP was 27.2% during pregnancy.
Kenyapaludismeobservé 2020publié 2022Malaria journaleurope_pmcdocument de 5 observationsDOI 10.1186/s12936-022-04425-x
3,1 %Among extrauterine infections in the study cohort from Migori, Kenya, syphilis accounted for 3.1%.
Kenyasyphilispublié 2023BMC pregnancy and childbirthPubMeddocument de 18 observations
2 244 peopleTreating 2244 people who inject drugs over 2021–2025 could reduce hepatitis C virus incidence by 90% by 2030 in Kenya.
Kenyahépatite Cobservé 2021-2025publié 2022AIDS (London, England)PubMeddocument de 8 observations
1,8 %The prevalence of undiagnosed diabetes among Kenyan adults aged 18–69 years was 1.8%.
Kenyadiabète (non précisé)observé 2015publié 2023PloS onePubMeddocument de 6 observations
400 000 000 peopleGlucose-6-phosphate dehydrogenase (G6PD) deficiency affects over 400 million people.
KenyaGlucose-6-phosphate dehydrogenase (G6PD) deficiencypublié 1995Natureeurope_pmcdocument de 3 observations
1,25 per_100_person_yearsThe mortality rate was 1.25 per 100 person-years among patients initiated on antiretroviral therapy in central Kenya.
KenyaVIH/sidapublié 2022BMC infectious diseasesPubMeddocument de 10 observations
1,16 mortality_rate_ratioIncrease in Normalized Difference Vegetation Index was associated with increased malaria mortality (mortality rate ratio = 1.16, 95% Bayesian credible interval: 1.06–1.28).
Kenyapaludismeobservé 2008–2019publié 2024BMJ global healthPubMeddocument de 8 observations
Chaque ligne mène à son document source. Le nombre indiqué est celui des observations VALIDÉES qu'il porte, jamais celui des observations extraites : les deux diffèrent sur la plupart des documents. L'extrait exact du texte source n'est pas publié, par contrainte de droit d'auteur.